Stavia, T., Castelnuovo, B., Sekaggya-Wiltshire, C., Dooley, K. E., Banturaki, G., Mbabazi, I., . . . Zawedde‐Muyanja, S. Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): An observational study protocol. BMJ Publishing Group.
Chicago Style (17th ed.) CitationStavia, Turyahabwe, et al. Clinical Predictors of 3-month Isoniazid Rifapentine (3HP)-related Adverse Drug Reactions (ADR) During Tuberculosis Preventive Therapy (PAnDoRA-3HP Study): An Observational Study Protocol. BMJ Publishing Group.
MLA (9th ed.) CitationStavia, Turyahabwe, et al. Clinical Predictors of 3-month Isoniazid Rifapentine (3HP)-related Adverse Drug Reactions (ADR) During Tuberculosis Preventive Therapy (PAnDoRA-3HP Study): An Observational Study Protocol. BMJ Publishing Group.